TF
FATE icon

Theory Financial’s Fate Therapeutics FATE Stock Holding History

Theory Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60K Buy
+22,222
New +$41.1K 0.02% 99

Other funds holding FATE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
PPW
Parcion Private Wealth Bellevue, Washington $1.8B AUM 30.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
NCM
Narwhal Capital Management Marietta, Georgia $1.45B AUM 28.39% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return

Theory Financial's FATE Position: Q2 2026 in Review

Theory Financial opened a new position in Fate Therapeutics (FATE) in Q2 2026: 22,222 shares worth $60K. The stake represents 0.02% of the portfolio and ranks #99 among its holdings.

29 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Theory Financial held 22,222 shares of Fate Therapeutics worth $60K as of Q2 2026.
  • Fate Therapeutics was a new Theory Financial position in Q2 2026.
  • Fate Therapeutics made up 0.02% of Theory Financial's portfolio in Q2 2026, its #99 holding.
  • 29 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Theory Financial's 13F filing for Q2 2026, filed 31 Jul 2026.